Mylan, Impax Win Ruling in Patent Case Over Copies of Doryx
This article is for subscribers only.
Mylan Inc. said it began selling a generic version of the antibiotic Doryx today after a judge ruled it didn’t infringe a patent held by Warner Chilcott Plc.
Mylan, based in Canonsburg, Pennsylvania, won a ruling in federal court in Newark, New Jersey, where U.S. District Judge William Martini lifted his Feb. 8 order barring the company from offering a generic version of Doryx in 150-milligram delayed-release tablets. The drug had $264 million in sales for 2011, according to figures of research firm IMS Health Inc. cited in a Mylan statement.